“…Considering that our recent study on the mechanism underlying DBS of the subthalamic nucleus revealed that DBS induces an increase in histamine release in the subthalamic nucleus to alleviate Parkinsonian motor deficits ( 20 ), we speculate that the DBS–NAc core may also induce histamine release in the NAc core to activate the presynaptic H3 receptor, inhibit glutamatergic afferent inputs from the prefrontal cortex, and subsequently ameliorate anxiety- and obsessive-compulsive-like behaviors. Unlike presynaptic GABA ( 48 , 49 ), adenosine ( 48 ), or serotonin ( 50 ) receptors functioning to modulate both excitatory and inhibitory synaptic transmission in NAc, the presynaptic histamine H3 receptor, selectively acting on glutamatergic neurotransmission, may be a better target for the treatment of glutamatergic dysfunction in NAc. Notably, several agonists for the H3 receptor, including RAMH and its prodrugs, have entered clinical trials and proved safe ( 51 , 52 ).…”